Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NASDAQ:CPIX NASDAQ:NKTR NASDAQ:OMER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$22.26-3.8%$21.61$7.75▼$27.17$177.61M0.68152,714 shs67,871 shsCPIXCumberland Pharmaceuticals$3.39-0.3%$3.35$1.04▼$7.25$50.86M-0.3737,566 shs10,469 shsNKTRNektar Therapeutics$48.18-0.8%$27.08$6.45▼$49.01$923.73M1.06950,617 shs1.65 million shsOMEROmeros$4.27+0.2%$3.93$2.95▼$13.60$289.92M2.37925,484 shs901,537 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-3.84%-6.86%-5.68%+30.18%+32.90%CPIXCumberland Pharmaceuticals-0.29%-6.09%+19.37%-42.15%+160.77%NKTRNektar Therapeutics-0.80%+68.76%+114.42%+450.00%+159.03%OMEROmeros+0.23%+2.15%+3.14%+20.28%+17.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$22.26-3.8%$21.61$7.75▼$27.17$177.61M0.68152,714 shs67,871 shsCPIXCumberland Pharmaceuticals$3.39-0.3%$3.35$1.04▼$7.25$50.86M-0.3737,566 shs10,469 shsNKTRNektar Therapeutics$48.18-0.8%$27.08$6.45▼$49.01$923.73M1.06950,617 shs1.65 million shsOMEROmeros$4.27+0.2%$3.93$2.95▼$13.60$289.92M2.37925,484 shs901,537 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-3.84%-6.86%-5.68%+30.18%+32.90%CPIXCumberland Pharmaceuticals-0.29%-6.09%+19.37%-42.15%+160.77%NKTRNektar Therapeutics-0.80%+68.76%+114.42%+450.00%+159.03%OMEROmeros+0.23%+2.15%+3.14%+20.28%+17.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.75Moderate Buy$41.3385.68% UpsideCPIXCumberland Pharmaceuticals 0.00N/AN/AN/ANKTRNektar Therapeutics 2.86Moderate Buy$88.3383.34% UpsideOMEROmeros 2.83Moderate Buy$18.00321.55% UpsideCurrent Analyst Ratings BreakdownLatest OMER, NKTR, ASMB, and CPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025ASMBAssembly BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $39.009/3/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.008/19/2025ASMBAssembly BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/18/2025ASMBAssembly BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/15/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/15/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.007/25/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.007/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $85.006/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$28.52M5.99N/AN/A$5.25 per share4.24CPIXCumberland Pharmaceuticals$37.87M1.34$0.26 per share13.22$1.61 per share2.11NKTRNektar Therapeutics$98.43M9.31N/AN/A$4.94 per share9.75OMEROmerosN/AN/AN/AN/A($3.15) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$40.18M-$5.58N/AN/AN/A-117.20%-149.01%-39.04%11/6/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/4/2025 (Estimated)NKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)OMEROmeros-$156.82M-$2.11N/AN/AN/AN/AN/A-55.49%11/12/2025 (Estimated)Latest OMER, NKTR, ASMB, and CPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025OMEROmeros-$0.55-$0.53+$0.02-$0.43$0.31 million$28.60 million8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million8/6/2025Q2 2025ASMBAssembly Biosciences-$1.73-$1.33+$0.40-$1.33$5.30 million$9.63 million8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A1.641.64CPIXCumberland Pharmaceuticals0.191.301.17NKTRNektar TherapeuticsN/A2.612.61OMEROmerosN/A0.810.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%CPIXCumberland Pharmaceuticals15.51%NKTRNektar Therapeutics75.88%OMEROmeros48.79%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.30%CPIXCumberland Pharmaceuticals44.85%NKTRNektar Therapeutics5.25%OMEROmeros12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences1007.67 million7.27 millionOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableNKTRNektar Therapeutics22019.02 million18.02 millionOptionableOMEROmeros21068.06 million59.28 millionOptionableOMER, NKTR, ASMB, and CPIX HeadlinesRecent News About These CompaniesMillionaire IT whiz Michael Nicktarios Omeros’s fight to bulldoze $19m Sunshine Beach mansionSeptember 9 at 11:55 AM | townsvillebulletin.com.auTAncora Advisors LLC Has $48,000 Position in Omeros Corporation $OMERSeptember 9 at 4:42 AM | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for Omeros (NASDAQ:OMER)September 5, 2025 | marketbeat.comNomura Holdings Inc. Trims Position in Omeros Corporation $OMERSeptember 4, 2025 | marketbeat.comPromising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy RatingSeptember 3, 2025 | tipranks.comNuveen LLC Makes New $938,000 Investment in Omeros Corporation $OMERSeptember 3, 2025 | marketbeat.comOmeros Corporation: Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ProgramSeptember 2, 2025 | finanznachrichten.deOmeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ProgramSeptember 2, 2025 | businesswire.comWellington Management Group LLP Acquires New Stake in Omeros Corporation $OMERSeptember 2, 2025 | marketbeat.comOmeros Corporation (NASDAQ:OMER) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comOmeros Corporation’s Positive Earnings Call Highlights ProgressAugust 31, 2025 | tipranks.comVanguard Group Inc. Has $26.61 Million Stock Position in Omeros Corporation $OMERAugust 31, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $87,000 Stock Position in Omeros Corporation $OMERAugust 23, 2025 | marketbeat.comFY2025 EPS Estimates for Omeros Raised by Cantor FitzgeraldAugust 22, 2025 | marketbeat.comOmeros: Deja Vu All Over Again (Rating Downgrade)August 20, 2025 | seekingalpha.comOmeros Corporation (OMER) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | seekingalpha.comOmeros Corporation (NASDAQ:OMER) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | insidermonkey.comD. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)August 17, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Given "Hold" Rating at Needham & Company LLCAugust 17, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Announces Earnings Results, Misses Estimates By $0.07 EPSAugust 16, 2025 | marketbeat.comOmeros Shares Gain on Narrower 2Q LossAugust 15, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025How ServiceNow Is Turning AI Strategy Into Real RevenueBy Jeffrey Neal Johnson | August 22, 2025AEHR Spikes 36% on Hyperscaler Order—Investors Should Take NoticeBy Leo Miller | August 27, 2025OMER, NKTR, ASMB, and CPIX Company DescriptionsAssembly Biosciences NASDAQ:ASMB$22.26 -0.89 (-3.84%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$22.08 -0.18 (-0.79%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Cumberland Pharmaceuticals NASDAQ:CPIX$3.39 -0.01 (-0.29%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$3.40 +0.00 (+0.15%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Nektar Therapeutics NASDAQ:NKTR$48.18 -0.39 (-0.80%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$48.31 +0.13 (+0.27%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Omeros NASDAQ:OMER$4.27 +0.01 (+0.23%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$4.32 +0.06 (+1.29%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
